Heterogeneity in antigenic expression and radiosensitivity in human colon carcinoma cell lines.
A panel of human colon carcinoma cell lines were characterized regarding both antigenic heterogeneity and variations in radiosensitivity. Monoclonal antibodies were used to study the expression of carcinoembryonic antigen (CEA), gastrointestinal cancer antigen (GICA or CA 19-9) and carcinoma-associated antigen (CA-50). Radiosensitivity was studied with the clonogenic survival technique. Three cell lines, LS 174T, HCTC, and SW 1116 stained positive for all three antigens. HT-29 was positive for CA 19-9 and CA-50 whereas Caco-2 was positive for CEA and CA 19-9. The cell lines SW 620 and LIM 1215 only stained positive for one of the antigens, CA-50 and CEA, respectively. In nearly all positive cases the stainings were very heterogeneous with mixtures of positive and negative cells. One exception was the HCTC cells which stained homogeneously for the CA 19-9 and CA-50 antigens. The neuroendocrinelike COLO 320 cells were negative in all cases. The radiosensitivity varied strongly between the cell lines with Dq-values between 0.8 and 1.9, extrapolation numbers between 2.0 and 4.7, Do-values between 1.1 and 2.8. The surviving fraction at 2 Gy varied between 0.3 and 0.7 with HCTC as the most radiosensitive and HT-29 as the most radioresistant cell line. Thus, there were differences in antigenic expression and intrinsic radiosensitivity between the cell-lines and antigenic heterogeneities within each cell line. The analyzed panel of cell lines will be valuable in studies of dose-effect relations for monoclonal antibodies labeled with toxic radionuclides simulating both antigenic heterogeneity and variations in radiosensitivity.
Frykholm
G
G
Department of Oncology, Uppsala University, Sweden.
Glimelius
B
B
Richter
S
S
Carlsson
J
J
D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology* / Q000532:radiotherapy; D000911:Antibodies, Monoclonal / Q000276:immunology; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000235:genetics / Q000276:immunology; D014408:Biomarkers, Tumor / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000235:genetics / Q000276:immunology; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology* / Q000532:radiotherapy; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D014644:Genetic Variation / Q000235:genetics / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D008223:Lymphoma / Q000276:immunology / Q000473:pathology* / Q000532:radiotherapy; D011836:Radiation Tolerance / Q000235:genetics*; D014407:Tumor Cells, Cultured / Q000276:immunology / Q000473:pathology / Q000528:radiation effects
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen